Security
NMRA · Neumora Therapeutics, Inc.
NMRANASDAQCommon stockCurrentCIK 1885522Updated Sep 24, 2026
NMRA price & chart
Loading TradingView…
NASDAQ:NMRA on TradingView ↗About the company
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
In the news
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference ↗
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA News provided by The Gross Law Firm Apr 07, 2025, 05:45 ET Share this article Share to X Share this article Share to X NEW YORK , April 7, 2025 /PRN ↗
NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm News provided by THE ROSEN LAW FIRM, P. A. Apr 04, 2025, 16:05 ET Share this article Share to X Share this article Share to X NEW YORK , April 4 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 191,047,000Source | 316,972,000Source | 496,195,000Source | 426,234,000Source |
| Property, Plant and Equipment, NetUSD | 40,000Source | 1,140,000Source | 1,790,000Source | 2,411,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 182,530,000Source | 142,148,000Source | 374,038,000Source | 240,943,000Source |
| Assets, CurrentUSD | 190,537,000Source | 314,055,000Source | 478,279,000Source | 387,955,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,007,000Source | 5,264,000Source | 24,297,000Source | 16,021,000Source |
| Operating Lease, Right-of-Use AssetUSD | 417,000Source | 1,777,000Source | 5,068,000Source | 8,231,000Source |
| Other Assets, NoncurrentUSD | 53,000Source | — | — | 2,913,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 87,176,000Source | 29,908,000Source | 27,119,000Source | 29,397,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — |
| Common Stock, Value, IssuedUSD | 17,000Source | 16,000Source | 16,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,184,149,000Source | -947,221,000Source | -703,434,000Source | -467,509,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 62,000Source | -76,000Source | -774,000Source |
| Stockholders' Equity Attributable to ParentUSD | 103,871,000Source | 287,064,000Source | 469,076,000Source | -446,850,000Source |
| Additional Paid in Capital, Common StockUSD | 1,288,003,000Source | 1,234,207,000Source | 1,172,570,000Source | 21,430,000Source |
| Liabilities and EquityUSD | 191,047,000Source | 316,972,000Source | 496,195,000Source | 426,234,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 32,451,000Source | 29,886,000Source | 25,111,000Source | 23,697,000Source |
| Operating Lease, Liability, CurrentUSD | 284,000Source | 1,853,000Source | 3,378,000Source | 3,370,000Source |
| Accounts Payable, CurrentUSD | 3,379,000Source | 3,307,000Source | 337,000Source | 7,147,000Source |
| Operating Lease, Liability, NoncurrentUSD | 193,000Source | — | 1,853,000Source | 5,072,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 28,788,000Source | 24,593,000Source | 21,257,000Source | 11,536,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 54,532,000Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 60,000,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 54,532,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -236,928,000Source | -243,787,000Source | -235,925,000Source | -130,904,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 208,000Source | 631,000Source | 668,000Source | 594,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 29,876,000Source | 39,990,000Source | 17,240,000Source | 8,298,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 71,000Source | 2,873,000Source | -581,000Source | -1,246,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -206,440,000Source | -182,936,000Source | -163,278,000Source | -114,896,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 168,520,000Source | -70,557,000Source | 64,387,000Source | -168,013,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 117,000Source | 511,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 77,089,000Source | 21,603,000Source | 231,936,000Source | 115,743,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 39,169,000Source | -231,890,000Source | 133,045,000Source | -167,166,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,219,000Source | — | — | — |
| Income Taxes Paid, NetUSD | 323,000Source | 473,000Source | — | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | 336,000Source | — | — | — |
| Share-based Payment Arrangement, ExpenseUSD | 29,876,000Source | 39,990,000Source | 17,240,000Source | 8,298,000Source |
| Amortization of Debt Issuance CostsUSD | 270,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 156,000Source | — | — | — |
| DepreciationUSD | 200,000Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | 18,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -47,000Source | — | — | — |
| General and Administrative ExpenseUSD | 60,091,000Source | 62,537,000Source | 45,475,000Source | 31,121,000Source |
| Income Tax Expense (Benefit)USD | 130,000Source | 178,000Source | 268,000Source | — |
| InterestExpenseNonoperatingUSD | 3,219,000Source | — | — | — |
| Investment Income, InterestUSD | 8,344,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -236,928,000Source | -243,787,000Source | -235,925,000Source | -130,904,000Source |
| Nonoperating Income (Expense)USD | 4,358,000Source | 19,855,000Source | 16,441,000Source | 4,966,000Source |
| Operating ExpensesUSD | 241,156,000Source | 263,464,000Source | 252,098,000Source | 135,870,000Source |
| Other Nonoperating Income (Expense)USD | -767,000Source | -78,000Source | -170,000Source | 405,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 810,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 0Source | 7,482,000Source | 2,856,000Source | 2,658,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -241,156,000Source | -263,464,000Source | -252,098,000Source | -135,870,000Source |
| Other Nonoperating Income (Expense)USD | -767,000Source | -78,000Source | -170,000Source | 405,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -236,798,000Source | -243,609,000Source | -235,657,000Source | -130,904,000Source |
| Income Tax Expense (Benefit)USD | 130,000Source | 178,000Source | 268,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -236,928,000Source | -243,787,000Source | -235,925,000Source | -130,904,000Source |
| Earnings Per Share, BasicUSD per share | -1.45Source | -1.53Source | -3.63Source | -4.81Source |
| Earnings Per Share, DilutedUSD per share | -1.45Source | -1.53Source | -3.63Source | -4.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 163,391,000Source | 159,377,000Source | 65,021,000Source | 27,207,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 163,391,000Source | 159,377,000Source | 65,021,000Source | 27,207,000Source |
| Interest Expense (non-operating)USD | 3,219,000Source | — | — | — |
| Additional Financial Items | ||||
| Gain (Loss) on InvestmentsUSD | — | — | — | 18,000Source |
| General and Administrative ExpenseUSD | 60,091,000Source | 62,537,000Source | 45,475,000Source | 31,121,000Source |
| Interest ExpenseUSD | 2,010,000Source | — | — | — |
| Interest Expense, DebtUSD | 3,219,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 8,344,000Source | 19,933,000Source | 16,611,000Source | 4,561,000Source |
| Investment Income, InterestUSD | 8,344,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 4,358,000Source | 19,855,000Source | 16,441,000Source | 4,966,000Source |
| Operating ExpensesUSD | 241,156,000Source | 263,464,000Source | 252,098,000Source | 135,870,000Source |
| Research and Development ExpenseUSD | 176,065,000Source | 200,927,000Source | 142,719,000Source | 91,749,000Source |
Filing attachments
nmra-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second half of 2026, respectively Joshua Pinto, Ph.…
Read attachment ↗nmra-ex99_1.htm · 8-K · 2026-07-27
EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a b…
Read attachment ↗d943192dex991.htm · 8-K · 2026-06-15
EX-99.1 2 d943192dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia and NMRA-215 in cardiometabolic disease Aligning organization to support initiation of mult…
Read attachment ↗nmra-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation and NMRA-898 in schizophrenia with clinical data expected for each program in the second half of 2026 Strong financial position with $147.1 milli…
Read attachment ↗nmra-ex99_1.htm · 8-K · 2026-03-30
EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of 2026; on track for topline readout in the second quarter of 2026 NMRA-898 selected as lead program in M4 franchise based on promis…
Read attachment ↗nmra-ex99_1.htm · 8-K · 2026-02-11
EX-99.1 2 nmra-ex99_1.htm EX-99.1 February 2026 Guggenheim Emerging Outlook: Biotech Summit Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality …
Read attachment ↗